Metabolic syndrome markers in Chernobyl accident recovery workers with chronic cerebrovascular disease

To study the role of metabolic syndrome in the pathogenesis of cerebrovascular disease, 60 Chernobyl accident recovery workers have undergone instrumental and laboratory examination. In addition to the parameters of glucose and lipid metabolism, metabolic syndrome markers, i. e. insulin with the calculation of HOMA index, leptin, adiponectin, plasminogen activator inhibitor 1 were assessed in recovery workers with chronic cerebrovascular disease. The excretion of the main melatonin metabolite – 6-sulfatoximelatonin in three urine samples (day, evening and night) was also assessed. As a result, diagnostically relevant laboratory parameters were selected for evaluating the role of metabolic syndrome in the development of chronic cerebrovascular disease and the effectiveness of the pathogenetic therapy. For the accident recovery workers with metabolic syndrome and chronic cerebrovascular disease it is reasonable, together with a standard examination, to define markers of plasma hemostasis activation, parameters of insulin and leptin resistance as well as excretion of melatonin metabolites. The introduction of the additional diagnostic tests will facilitate the timely detection of metabolic syndrome in recovery workers. Understanding the real causes of metabolic syndrome and pathogenetic mechanisms of insulin resistance will help to develop more effective ways of prevention and correction of this metabolism disorder and eventually reduce the risk of cardiovascular disease and mortality in these patients.

1. 25 let posle Chernobylya: sostoyanie zdorov’ya, patogeneticheskie mekhanizmy, opyt meditsinskogo soprovozhdeniya likvidatorov posledstvii avarii na Chernobyl’skoi atomnoi elektrostantsii [25 years after Chernobyl: health, pathogenic mechanisms, the experience of medical support of the liquidators of consequences of the accident at the Chernobyl nuclear power station]. Ed. S. S. Aleksanin. Sankt-Peterburg. 2011. 736 p. (In Russ.)

2. Diagnostika i lechenie metabolicheskogo sindroma. Rossiiskie rekomendatsii (vtoroi peresmotr). VNOK, komitet ekspertov [Diagnosis and treatment of metabolic syndrome. Russian recommendations (second revision). The Committee of experts]. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular therapy and prevention]. 2009. Vol. 8, N 6, Application 2. 29 p. (In Russ.)

3. Reshetnyak M. V., Zybina N. N., Khirmanov V. N., Frolova M. Yu. Dopolnitel’nye laboratornye markery metabolicheskogo sindroma u likvidatorov posledstvii avarii na Chernobyl’skoi AES [Additional laboratory markers of metabolic syndrome in liquidators of the Chernobyl aftermath]. Mediko-biologicheskie i sotsial’no-psikhologicheskie problemy bezopasnosti v chrezvychaynykh situatsiyakh [Medical-Biological and Socio-Psychological Problems of Safety in Emergency Situations]. 2011. N 2. Pp. 79–83. (In Russ.)

4. Khirmanov V. N., Zybina N. N., Reshetnyak M. V., Frolova M. Yu. Metabolicheskii serdechno-sosudistyi sindrom i ateroskleroz [Metabolic cardiovascular syndrome and atherosclerosis]. 25 let posle Chernobylya: sostoyanie zdorov’ya, patogeneticheskie mekhanizmy, opyt meditsinskogo soprovozhdeniya likvidatorov posledstvii avarii na Chernobyl’skoi atomnoi elektrostantsii [25 years after Chernobyl: health, pathogenic mechanisms, the experience of medical support of the liquidators of consequences of the accident at the Chernobyl nuclear power station]. Ed. S. S. Aleksanin. Sankt-Peterburg. 2011. Pp. 55–79. (In Russ.)

5. Cipolla-Neto J., Amaral F. G. Afeche S. C. [et al.]. Melatonin, energy metabolism, and obesity: a review. J. Pineal Res. 2014. Vol. 56, N 4. Pp. 371–381.

6. Fanning J. P., Wong A. A., Fraser J. F. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med. 2014. Vol. 12. P. 119.

7. Flegal K. M., Carroll M. D., Kit B. K., Ogden C. L. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012. Vol. 307. Pp. 491–497.

8. Martin B. J.,Verma S., Charbonneau F., Title L. M. [et al.]. The relationship between anthropometric indexes of adiposity and vascular function in the FATE cohort. Obesity (Silver Spring). 2013. Vol. 21. Pp. 266–273.

9. Navarro-Alarcon M., Ruiz-Ojeda F. J., Blanca-Herrera R. M. [et al.]. Melatonin and metabolic regulation: a review. Food Funct. 2014. Vol. 5. Pp. 2806–2832.

10. Srinivasan V., Ohta Y., Espino J. [et al.]. Metabolic syndrom, ist pathophysiology and the role of melatonin. Recent Pat Endocr. Metab. Immune Drug Discove. 2013. Vol. 7, N 1. Pp. 11–25.

11. Touboul P. J. [et al.]. Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004–2006–2011). Cerebrovasc. Dis. 2012. Vol. 34, N 4. Pp. 290–296.